BR112022005615A2 - Peptídeos de staphylococcus e métodos de uso - Google Patents

Peptídeos de staphylococcus e métodos de uso

Info

Publication number
BR112022005615A2
BR112022005615A2 BR112022005615A BR112022005615A BR112022005615A2 BR 112022005615 A2 BR112022005615 A2 BR 112022005615A2 BR 112022005615 A BR112022005615 A BR 112022005615A BR 112022005615 A BR112022005615 A BR 112022005615A BR 112022005615 A2 BR112022005615 A2 BR 112022005615A2
Authority
BR
Brazil
Prior art keywords
polypeptide
staphylococcus
peptides
methods
lukab
Prior art date
Application number
BR112022005615A
Other languages
English (en)
Inventor
Theunis Poolman Jan
Schneewind Olaf
Missiakas Dominique
Sun Yan
Keun Kim Hwan
Shi Miaomiao
Chen Xinhai
A Fernandez Jeffrey
Original Assignee
Janssen Vaccines & Prevention Bv
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv, Univ Chicago filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112022005615A2 publication Critical patent/BR112022005615A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Abstract

A presente invenção refere-se a composições imunogênicas compreendendo uma variante de proteína A (SpA) de Staphylococcus aureus e um polipeptídeo da subunidade de leucocidina estafilocócica mutante compreendendo um polipeptídeo de LukA, um polipeptídeo de LukB e/ou um polipeptídeo dímero de LukAB, em que o polipeptídeo de LukA, o polipeptídeo de LukB e/ou o polipeptídeo dímero de LukAB têm uma ou mais substituições de aminoácidos, deleções ou uma combinação das mesmas.
BR112022005615A 2019-10-02 2020-10-02 Peptídeos de staphylococcus e métodos de uso BR112022005615A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909473P 2019-10-02 2019-10-02
US201962909458P 2019-10-02 2019-10-02
PCT/US2020/054047 WO2021067785A1 (en) 2019-10-02 2020-10-02 Staphylococcus peptides and methods of use

Publications (1)

Publication Number Publication Date
BR112022005615A2 true BR112022005615A2 (pt) 2022-07-12

Family

ID=73040235

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005615A BR112022005615A2 (pt) 2019-10-02 2020-10-02 Peptídeos de staphylococcus e métodos de uso

Country Status (12)

Country Link
US (1) US20220362368A1 (pt)
EP (1) EP4038091A1 (pt)
JP (1) JP2022550884A (pt)
KR (1) KR20220107166A (pt)
CN (1) CN115151559A (pt)
AU (1) AU2020358862A1 (pt)
BR (1) BR112022005615A2 (pt)
CA (1) CA3155424A1 (pt)
CO (1) CO2022004541A2 (pt)
IL (1) IL291821A (pt)
MX (1) MX2022004061A (pt)
WO (1) WO2021067785A1 (pt)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH11514870A (ja) 1995-10-16 1999-12-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規な唾液結合タンパク質
EP0950068B1 (en) 1996-05-16 2005-11-09 THE TEXAS A&M UNIVERSITY SYSTEM Collagen binding protein compositions and methods of use
JP5019494B2 (ja) 1997-04-01 2012-09-05 コリクサ コーポレーション モノホスホリルリピドａの水性免疫アジュバント組成物
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2337966A1 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
IL141691A0 (en) 1998-08-31 2002-03-10 Trinity College Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
AU762978B2 (en) 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
DE69940371D1 (de) 1998-09-14 2009-03-19 Nabi Biopharmaceuticals Rockvi Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
TR200101055T2 (tr) 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
DE60134499D1 (de) 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2068918B1 (en) 2006-09-26 2012-05-02 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL3281947T3 (pl) 2009-04-03 2020-07-27 The University Of Chicago Kompozycje i sposoby związane z wariantami białka A (SpA)
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
KR101982126B1 (ko) 2010-03-08 2019-05-27 몬산토 테크놀로지 엘엘씨 식물에서 유전자 조절을 위한 폴리뉴클레오타이드 분자
JP6031029B2 (ja) 2010-05-05 2016-11-24 ニューヨーク・ユニバーシティ 黄色ブドウ球菌ロイコシジン、その治療用組成物、および使用
US11510875B2 (en) 2012-02-07 2022-11-29 Access To Advanced Health Institute Adjuvant formulations comprising TLR4 agonists and methods of using the same
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9890199B2 (en) 2013-12-09 2018-02-13 Olymvax Biopharmaceuticals Inc. Staphylococcus aureus SpA5 mutant, composition comprising mutant and preparation method and use thereof
WO2015144691A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
RS59971B1 (sr) 2014-03-26 2020-03-31 Glaxosmithkline Biologicals Sa Mutantni stafilokokni antigeni
US10781246B2 (en) * 2015-06-05 2020-09-22 New York University Compositions and methods for anti-staphylococcal biologic agents
EP3638286A4 (en) 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
AU2018330165A1 (en) 2017-09-08 2020-04-02 Access To Advanced Health Institute Liposomal formulations comprising saponin and methods of use

Also Published As

Publication number Publication date
AU2020358862A1 (en) 2022-04-14
IL291821A (en) 2022-06-01
KR20220107166A (ko) 2022-08-02
US20220362368A1 (en) 2022-11-17
CO2022004541A2 (es) 2022-04-29
MX2022004061A (es) 2022-07-19
JP2022550884A (ja) 2022-12-05
CA3155424A1 (en) 2021-04-08
EP4038091A1 (en) 2022-08-10
WO2021067785A1 (en) 2021-04-08
CN115151559A (zh) 2022-10-04

Similar Documents

Publication Publication Date Title
BR112016029848A2 (pt) proteínas de fusão mic-1 e utilizações das mesmas
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112018072034A2 (pt) compostos mic-1 e usos dos mesmos
PE20211469A1 (es) Proteinas f de prefusion del vrs estabilizadas
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2019084343A8 (en) Peptide compositions and methods of use thereof
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
PH12019501064A1 (en) Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION
EA201990451A1 (ru) Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение
MX2020012989A (es) Agente terapeutico para la fibrosis.
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112019024667A2 (pt) Uso de um agente bioativo, e, de uma composição
PH12018501758A1 (en) Oritavancin formulations
BR112022005615A2 (pt) Peptídeos de staphylococcus e métodos de uso
BR112022017032A2 (pt) Composições compreendendo ltb e antígenos patogênicos, e uso das mesmas.
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
MX2022002766A (es) Vacunas contra el virus de la gripe y usos de las mismas.
BR112018001391A2 (pt) terapias de combinação
BR102018013710A2 (pt) composição farmacêutica para dor neuropática
NZ751995A (en) Modified factor h binding protein
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
MX2020001046A (es) Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.